Table 4.
Summary of participant cardiotoxicity risk factors
| Characteristics (n = 36) | Participants n (%) | |
|---|---|---|
| Age > 50 years | 27 (76) | |
| Cancer type | ||
| Breast | 22 (61.2) | |
| Breast left | 2 (5.6) | |
| Carcinoma of breast (elective (L) mastectomy 4/8/15) | 1 (2.8) | |
| Lower-inner quadrant of breast | 1 (2.8) | |
| Malignant breast cancer | 1 (2.8) | |
| Malignant neoplasm of breast | 3 (8.3) | |
| Malignant neoplasm of upper-outer quadrant of breast | 1 (2.8) | |
| Metastatic HER-2 pos breast cancer | 1 (2.8) | |
| Palpable cancer right breast | 1 (2.8) | |
| Missing | 3 (8.3) | |
| Chemotherapy | ||
| Mean number of chemotherapy cycles 4.9 (Median 3) Range (1–16) | ||
| Agent class | Mean Dose (mg) | n (%) |
| Alkylating agents | ||
| Carboplatin | 658 | 5 (13.8%) |
| Cyclophosphamide | 1073 | 20 (56%) |
| Anthracyclines | ||
| Doxorubicin | 110 | 11 (30%) |
| Antimetabolites | ||
| Fluorouracil | 996 | 6 (17%) |
| Mitotic Inhibitors | ||
| Docetaxel | 158 | 15 (42%) |
| Paclitaxel | 156 | 20 (56%) |
| Monoclonal Antibody | ||
| Denosumab | 120 | 1 (2%) |
| Trastuzumab | 493 | 13 (36%) |
| Baseline Cardiac Assessment | ||
| Echocardiography | 14 (38.9) | |
| Left Ventricular Ejection Fraction <45% | 0 (0) | |
| Angiography | 1 (2.8) | |
| Electrocardiogram | 11 (30.6) | |
Summary of cardiotoxicity risk factors